NEURALPULSE LTD.

NeuralPulse Ltd. is a medical device company developing an adaptive neuromodulation therapy for drug-resistant epilepsy. The company's core product is an intracranially implantable neuromodulation device that uses a three-stage approach: probing the brain with electrical pulses to assess neural state, predicting seizure likelihood based on brain response patterns, and preventing seizures through therapeutic electrical stimulation. The technology represents a paradigm shift from passive seizure detection to active predictive neuromodulation. The company completed first-in-human clinical trials at King's College Hospital, London, demonstrating in eight drug-resistant epilepsy patients that active probing significantly improves seizure prediction accuracy compared to passive monitoring techniques and that tracking brain response to electrical stimulation is safe, ethically permissible, and well-tolerated. The founding team comprises leading neuroscientists and clinicians from King's College London, including the Chief Executive Officer (research fellow in health informatics and biostatistics), Chief Medical Officer (Professor of Epilepsy), and Chief Scientific Officer (Senior Lecturer in Clinical Neurophysiology and Honorary Clinical Neurology Consultant). Academic advisors include engineering and biomedical device experts from Oxford University and University of Washington. The company has received recognition including the Best Innovation prize at the London Institute for Healthcare Engineering Showcase (February 2025) and completed the inaugural King's MedTech Accelerator programme. Partnerships include King's College London, King's Health Partners, King's College Hospital, and CorTec (neuromodulation device manufacturer). The company is positioned within the emerging field of closed-loop neuromodulation for seizure management, targeting patients with epilepsy unresponsive to pharmaceutical interventions.